On October 27, HBM HOLDINGS-B fell 5.11% in regular trading, with the stock trading at HK$9.675 and turnover at HK$46.67 million.
The most recent company-specific development in the public domain was the approval of bartolimab injection by China’s drug regulator for adult generalized myasthenia gravis patients who are anti-acetylcholine receptor antibody positive, to be used with conventional therapy. The product is the company’s first approved product and the first anti-FcRn therapy completed through full clinical development for gMG patients in China.
Earlier disclosures said 58.2% of treated patients met the primary endpoint versus 31.3% in the placebo group, while the company also said it is entitled to tiered royalties based on annual net sales in Greater China. However, the latest market data show the biotechnology sector was broadly weak on the day, with AKESO down 3.75%, DUALITYBIO-B down 30.64%, KEYMED BIO-B down 12.35%, INNOVENT BIO down 2.96%, and SKB BIO down 6.08%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments